High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer

Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations

(2017) Yanwei Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma

(2015) Yufeng Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

(2015) D. Ercan et al.   CLINICAL CANCER RESEARCH

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

Metabolic control of YAP and TAZ by the mevalonate pathway

(2014) Giovanni Sorrentino et al.   NATURE CELL BIOLOGY

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials

(2013) William D. Travis et al.   JOURNAL OF CLINICAL ONCOLOGY

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth

(2012) Teemu J. Murtola et al.   PLoS One

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification

(2011) Caryl J. Antalis et al.   CLINICAL & EXPERIMENTAL METASTASIS

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

(2010) Mary E. Irwin et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA